DE | EN | FR

Who we are and what we do

The Swiss Medical Board is a leading Swiss centre of competence in health technology assessment. It analyses and assesses preventive and diagnostic procedures and therapeutic interventions from the perspective of medicine, economic considerations, ethics and law. On this basis, it develops recommendations to political decision-makers, medical specialists and other service providers. In selected cases, information leaflets are also published for patients. 

The sponsoring membership of the Swiss Medical Board (SMB) includes the following institutions and bodies: Konferenz der kantonalen GesundheitsdirektorInnen – GDK (the Swiss conference of cantonal ministers of public health), Schweizerische Akademie der Medizinischen Wissenschaften – SAMW (Swiss academy of medical sciences), the Government of the Principality of Lichtenstein, interpharma (the association of pharmaceutical research companies of Switzerland), associations of health insurers (santésuisse, curafutura), patient organisations (Schweizerische Stiftung SPO Patientenschutz  and Dachverband Schweizerischer Patientenstellen – DVSP), and fmCh (the umbrella organisation for doctors carrying out surgery and invasive procedures).

Brief profile


In the last two reports of the SMB, a Benefit Harm Assessment was carried out as an additional methodological component. Based on the positive...

Read more

Various options are available to treat depression, namely psychotherapy and/or drug therapy with antidepressants. In a new HTA report, the Swiss...

Read more

Significant advances have been made in the treatment of prostate cancer in recent years, significantly improving the prognosis of patients with severe...

Read more